Posts by Mourabit Halima

Severe Aplastic Anemia (SAA), as a highly heterogeneous bone marrow failure (BMF) disorder, continues to present a clinical challenge regarding the optimal choice between immunosuppressive therapy (IST) and hematopoietic stem cell transplantation (HSCT). During the recent European Society for Blood and Marrow Transplantation (EBMT) meeting, Professor Antonio Risitano provided a comprehensive overview of the Severe Aplastic Anemia Working Party (SAAWP) core activities, landmark clinical trials, and biological discoveries. This review deconstructs the key highlights of his presentation to provide clinicians with a cutting-edge international reference for evidence-based medicine.

The advent of Chimeric Antigen Receptor T-cell (CAR-T) therapy has fundamentally transformed the treatment landscape for relapsed/refractory (R/R) hematologic malignancies. However, as clinical adoption expands and follow-up durations extend, the management of treatment-related toxicities—specifically Non-Relapse Mortality (NRM)—has emerged as a critical bottleneck for long-term patient survival. At the 2026 Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), Dr. Charlotte Graham from London, representing the EBMT Transplant Complications Working Party (TCWP), presented a large-scale real-world study based on the EBMT registry. This analysis of nearly 7,000 CAR-T recipients provides high-granularity insights into NRM risk profiles and clinical intervention strategies.

At the recent Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), Professor Florent Malard from Sorbonne Université, lead of the Microbiome Research Project within the EBMT Cellular Therapy & Immunobiology Working Party, presented the final results of the ARES Phase III clinical trial. The presentation focused on the efficacy and safety of MAAT013, a novel microbiome-based therapeutic, for patients with ruxolitinib-refractory acute graft-versus-host disease with gastrointestinal involvement (GI-aGVHD).

At the EBMT 2026 Annual Meeting, Professor Franco Locatelli from Bambino Gesù Children’s Hospital presented long-term follow-up data for exagamglogene autotemcel (exa-cel), a CRISPR/Cas9-based gene-editing therapy. The study included patients with transfusion-dependent thalassemia (TDT) and sickle cell disease (SCD) with recurrent vaso-occlusive crises (VOCs). With a median follow-up of over three years and some patients reaching over six years, the results provide robust evidence for the long-term efficacy and safety of gene editing in hereditary blood disorders.

From March 22 to 25, 2026, the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in Madrid, Spain. As one of the most influential conferences in the field, the meeting brought together thousands of experts worldwide to discuss the latest advances in transplantation and cellular therapy.

Iron deficiency anemia (IDA) is the most common nutritional deficiency and the leading cause of anemia worldwide. Despite the availability of well-established diagnostic methods, IDA is often underestimated in clinical practice as a “minor condition.”

In March, as spring brings renewed vitality to Beijing, the 9th Beijing Conference on Thrombosis and Hemostasis, together with the 7th Beijing Hematologic Oncology and Immunology Summit Forum, was held from March 27 to 28, 2026. Centered on advances in the diagnosis and treatment of thrombotic and hemostatic disorders, as well as hematologic malignancies and immunology, the meeting highlighted cutting-edge developments and evolving clinical strategies.

In March, as spring breathes new life into Beijing, the 9th Beijing Conference on Thrombosis and Hemostasis, organized by the Hematology and Immunology Branch of the Chinese Society of Immunology, together with the 7th Beijing Hematologic Oncology and Immunology Summit Forum, was successfully convened from March 27 to 28, 2026. During the meeting, Professor Zhenyu Yan from the Affiliated Hospital of North China University of Science and Technology delivered a keynote lecture entitled “Seven Transformations in the Comprehensive Diagnosis and Management of Hemophilia in China.”